Clinical investigation of Multispectral Optoacoustic Tomography for monitoring neoadjuvant therapy in breast cancer. (A01)

A1致力于多光谱光声断层扫描（MSOT）的临床评估，特别是在体内乳腺成像的背景下，以确定适用于早期预测新辅助治疗反应的内源性生物标志物。通过使用混合手持式MSOT和超声成像模式，A1将进一步评估MSOT补充乳腺超声诊断性能的能力。我们假设，可视化和监测人类乳腺的功能和分子信号将通过允许早期个体化治疗适应性来改善治疗性能。

A1 is dedicated to the clinical assessment of multispectral optoacoustic tomography (MSOT), in particular in the context of in vivo breast imaging to determine endogenous biomarkers suitable for early prediction of response to neoadjuvant therapy. By utilizing a hybrid handheld MSOT and ultrasound imaging modality, A1 will further evaluate the MSOT ability to complement the diagnostic performance of breast ultrasound. We hypothesize that visualizing and monitoring of functional and molecular signals in human breast will lead to improvements in treatment performance by allowing for individual therapy adaptation early on.